3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
5
Tumor-Agnostic
3
Thoracic
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
17
Urinary Bladder Neoplasms
10
Kidney Neoplasms
6
Pancreatic Neoplasms
4
Neoplasms
4
Head and Neck Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Stomach Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Muscle-invasive Bladder Cancer
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Laryngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Central Nervous System Neoplasms
2
Carcinoma, Transitional Cell
2
Interventions
pembrolizumab
6
Radiosurgery
5
Docetaxel
5
enzalutamide
4
darolutamide
3
Radiotherapy
3
Everolimus
3
Androgen Antagonists
3
relugolix
2
luprolide acetate gel depot
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy, Image-Guided
2
Radiofrequency Ablation
2
Panobinostat
2
Leuprolide
2
Abiraterone Acetate
2
trastuzumab deruxtecan
1
talazoparib
1
spartalizumab
1
siremadlin
1
sipuleucel-T
1
sargramostim
1
resiquimod
1
polysaccharide-K
1
poly ICLC
1
palbociclib
1
olaparib
1
liposomal doxorubicin
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Drug Therapy
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled